


PHARMACEUTICAL 2017



Corbus Pharmaceuticals Holdings Inc. Rank 214 of 292





PHARMACEUTICAL 2017



Corbus Pharmaceuticals Holdings Inc. Rank 214 of 292

The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is -35%, being 38% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	17,403
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,899
Liabilities, Non-Current	4.6
Other Assets	50
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	66
Other Net Income	-14
Other Revenues	1,911
Property and Equipment	435
Research and Development	15,437
Selling, General and Administrative Expense	6,460

Output Variable	Value in 1000 USD
Assets	17,888
Liabilities	8,969
Expenses	21,896
Revenues	1,911
Stockholders Equity	8,919
Net Income	-19,999
Comprehensive Net Income	-19,999
Economic Capital Ratio	-35%

